Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aspacytarabine - BioSight

Next Previous
Drug Profile

Aspacytarabine - BioSight

Alternative Names: Ara-C asparagine conjugate; Aspacytarabine-hydrochloride-BioSight; Asparagine ara-C conjugate; Asparagine cytarabine conjugate; Astarabine; BSR-236; BST 236; BST-236-HCl; Cytarabine asparagine conjugate; Cytarabine-prodrug

Latest Information Update: 29 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioSight
  • Developer BioSight; Groupe Francophone des Myelodysplasies
  • Class Amino acids; Antineoplastics; Arabinonucleosides; Drug conjugates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Chronic myeloid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 09 Dec 2023 Efficacy and adverse events data from a phase II trial in Acute myeloid leukaemia and Myelodysplastic syndromes presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 16 Mar 2023 BioSight completes a phase II (ELPIS) trial in Acute myeloid leukaemia (Newly diagnosed, First-line therapy) in USA and Israel (IV) (NCT03435848)
  • 17 Aug 2022 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, First-line therapy, In adults, In elderly) in USA (IV) (NCT05503355)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top